Product category
Bacteria
Strain designation
PGO2364
Type strain
No
Genome sequenced strain
Yes
Isolation source
Sputum sample
Applications
Antimicrobial resistance research
Drug development
Product format
Frozen
Storage conditions
-80°C or colder
General
Preceptrol
No
Characteristics
Susceptibility profile
Intermediate
Tobramycin
Susceptible
Amikacin
Aztreonam
Cefepime
Ceftazidime
Ciprofloxacin
Doripenem
Imipenem
Levofloxacin
Meropenem
Piperacillin
Ticarcillin-clavulanate
Comments
This isolate was collected from a sputum sample of a cystic fibrosis patient during a Phase III clinical trial that tested the effectiveness of aerosolized Tobi (Tobramycin). The 1995-1996 clinical trial was conducted by a consortium led by Chiron and later acquired by Novartis AG.
The presence of a phage has been observed in this strain.
Handling information
Medium
ATCC Medium 18: Trypticase Soy Agar/Broth
Temperature
37°C
Atmosphere
Aerobic
Handling procedure
Open thawed vial.
Aseptically transfer the entire contents to a 5-6 mL tube of #18 broth. Additional test tubes can be inoculated by transferring 0.5 mL of the primary broth tube to these secondary tubes.
Use several drops of the primary broth tube to inoculate a #18 plate and/or #18 agar slant.
Incubate at 37°C for 24 hours.
Handling notes
This strain of Pseudomonas aeruginosa was isolated from a clinical drug trial for cystic fibrosis patients.
Additional information on this culture is available on the ATCC® web site at www.atcc.org.
